{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:44:26Z","timestamp":1787237066951,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2001,9,1]],"date-time":"2001-09-01T00:00:00Z","timestamp":999302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,9,1]],"date-time":"2001-09-01T00:00:00Z","timestamp":999302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2001,9,1]]},"DOI":"10.1038\/sj.bmt.1703213","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T12:38:25Z","timestamp":1032266305000},"page":"551-556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults"],"prefix":"10.1038","volume":"28","author":[{"given":"BH","family":"Kushner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N-K V","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IJ","family":"Dunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Boulad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2001,10,12]]},"reference":[{"key":"BF1703213_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1200\/JCO.1991.9.2.274","volume":"9","author":"BH Kushner","year":"1991","unstructured":"Kushner BH, O'Reilly RJ, Mandell LR et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma J Clin Oncol 1991 9: 274\u2013279","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.1998.16.1.222","volume":"16","author":"IJ Dunkel","year":"1998","unstructured":"Dunkel IJ, Boyett JM, Yates A et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma J Clin Oncol 1998 16: 222\u2013228","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","volume":"341","author":"KK Matthay","year":"1999","unstructured":"Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid New Engl J Med 1999 341: 1165\u20131173","journal-title":"New Engl J Med"},{"key":"BF1703213_CR4","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2001.19.3.870","volume":"19","author":"BH Kushner","year":"2001","unstructured":"Kushner BH, Meyers PA . How effective is dose-intensive\/myeloablative therapy against Ewing's sarcoma\/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering Cancer Center experience and a literature review J Clin Oncol 2001 19: 870\u2013880","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/BF00685553","volume":"31","author":"PJ Houghton","year":"1992","unstructured":"Houghton PJ, Cheshire PJ, Myers L et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors Cancer Chemother Pharmacol 1992 31: 229\u2013239","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703213_CR6","first-page":"2268","volume":"52","author":"CB Hendricks","year":"1992","unstructured":"Hendricks CB, Rowinsky EK, Grochow LB et al. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue Cancer Res 1992 52: 2268\u20132278","journal-title":"Cancer Res"},{"key":"BF1703213_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/jnci\/88.11.734","volume":"88","author":"SH Kaufmann","year":"1996","unstructured":"Kaufmann SH, Peereboom D, Buckwalter CA et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines J Natl Cancer Inst 1996 88: 734\u2013741","journal-title":"J Natl Cancer Inst"},{"key":"BF1703213_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF00688317","volume":"37","author":"SD Baker","year":"1996","unstructured":"Baker SD, Heideman RL, Crom WR et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors Cancer Chemother Pharmacol 1996 37: 195\u2013202","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703213_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/JCO.1994.12.3.539","volume":"12","author":"CB Pratt","year":"1994","unstructured":"Pratt CB, Stewart C, Santana VM et al. Phase 1 study of topotecan for pediatric patients with malignant solid tumors J Clin Oncol 1994 12: 539\u2013543","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR10","first-page":"243","volume":"25","author":"C Kretschmar","year":"1995","unstructured":"Kretschmar C, Kletzel M, Murray K et al. Upfront phase II therapy with taxol and topotecan in untreated children with disseminated neuroblastoma: A Pediatric Oncology Group study Med Pediatr Oncol 1995 25: 243 (Abstr.)","journal-title":"Med Pediatr Oncol"},{"key":"BF1703213_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00043426-199611000-00004","volume":"18","author":"DG Tubergen","year":"1996","unstructured":"Tubergen DG, Stewart CF, Pratt CB et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study J Pediatr Hematol\/Oncol 1996 18: 352\u2013361","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"BF1703213_CR12","first-page":"510a","volume":"16","author":"T Vietti","year":"1997","unstructured":"Vietti T, Crist W, Ruby E et al. Topotecan window in patients with rhabdomyosarcoma: an IRSG study Proc Am Soc Clin Oncol 1997 16: 510a (Abstr.)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1703213_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/00043426-199807000-00006","volume":"20","author":"R Nitschke","year":"1998","unstructured":"Nitschke R, Parkhurst J, Sullivan J et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study J Pediatr Hematol\/Oncol 1998 20: 315\u2013318","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"BF1703213_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/jnci\/88.12.817","volume":"88","author":"S O'Reilly","year":"1996","unstructured":"O'Reilly S, Rowinsky E, Slichenmyer W et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function J Natl Cancer Inst 1996 88: 817\u2013824","journal-title":"J Natl Cancer Inst"},{"key":"BF1703213_CR15","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1200\/JCO.1996.14.12.3062","volume":"14","author":"S O'Reilly","year":"1996","unstructured":"O'Reilly S, Rowinsky E, Slichenmyer W et al. Phase I and pharmacologic studies of topotecan in patients with impaired renal function J Clin Oncol 1996 14: 3062\u20133073","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/1096-911X(20001201)35:6<719::AID-MPO52>3.0.CO;2-V","volume":"35","author":"JR Park","year":"2000","unstructured":"Park JR, Slattery J, Gooley T et al. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory\/recurrent pediatric solid tumors Med Pediatr Oncol 2000 35: 719\u2013723","journal-title":"Med Pediatr Oncol"},{"key":"BF1703213_CR17","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 1989 7: 1748\u20131756","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR18","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","volume":"11","author":"GM Brodeur","year":"1993","unstructured":"Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment J Clin Oncol 1993 11: 1466\u20131477","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR19","unstructured":"Kushner BH, Kramer K, Cheung N-KV . Phase II trial of the anti-G02 monoclonal antibody 3f8 and granulocyte\u2013macrophage colony-stimulating factor for neuroblastoma J Clin Oncol (in press)"},{"key":"BF1703213_CR20","unstructured":"Kushner BH, Kramer K, Cheung N-KV . Phase II trial of the anti-GD2 monoclonal antibody 3F\u03b4 and granulocyte\u2013macrophage colony-stimulating factor for neuroblastoma J Clin Oncol (in press)"},{"key":"BF1703213_CR21","first-page":"6417","volume":"48","author":"III Frei E","year":"1988","unstructured":"Frei E III, Teicher BA, Holden SA et al. Preclinical studies and clinical correlation of the effect of alkylating dose Cancer Res 1988 48: 6417\u20136423","journal-title":"Cancer Res"},{"key":"BF1703213_CR22","first-page":"4379","volume":"46","author":"BA Teicher","year":"1986","unstructured":"Teicher BA, Cucchi CA, Lee JB et al. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines Cancer Res 1986 46: 4379\u20134388","journal-title":"Cancer Res"},{"key":"BF1703213_CR23","first-page":"2","volume":"17","author":"SN Wolff","year":"1990","unstructured":"Wolff SN, Herzig RH, Fay JW et al. High-dose N, N\u2032, N\u2033\u2013triethylenethio-phosphoramide (Thiotepa) with autologous bone marrow transplantation: phase I studies Semin Oncol 1990 17: 2\u20136","journal-title":"Semin Oncol"},{"key":"BF1703213_CR24","first-page":"369","volume":"8","author":"UM Saarinen","year":"1991","unstructured":"Saarinen UM, Hovi L, M\u00e4kipernaa A, Riikonen P . High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors Bone Marrow Transplant 1991 8: 369\u2013376","journal-title":"Bone Marrow Transplant"},{"key":"BF1703213_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/1097-0142(19930701)72:1<271::AID-CNCR2820720147>3.0.CO;2-K","volume":"72","author":"RL Heidemann","year":"1993","unstructured":"Heidemann RL, Packer RJ, Reaman GH et al. A phase II evaluation of thiotepa in pediatric central nervous system malignancies Cancer 1993 72: 271\u2013275","journal-title":"Cancer"},{"key":"BF1703213_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/sj.bmt.1701395","volume":"22","author":"N Lucidarme","year":"1998","unstructured":"Lucidarme N, Valteau-Couanet D, Oberlin O et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors Bone Marrow Transplant 1998 22: 535\u2013540","journal-title":"Bone Marrow Transplant"},{"key":"BF1703213_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/JCO.1989.7.5.651","volume":"7","author":"TC Shea","year":"1989","unstructured":"Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support J Clin Oncol 1989 7: 651\u2013661","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR28","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1002\/1097-0142(19901215)66:12<2465::AID-CNCR2820661204>3.0.CO;2-N","volume":"66","author":"PS Gaynon","year":"1990","unstructured":"Gaynon PS, Ettinger LJ, Baum ES et al. Carboplatin in childhood brain tumors. A Children's Cancer Study Group phase II trial Cancer 1990 66: 2465\u20132469","journal-title":"Cancer"},{"key":"BF1703213_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1200\/JCO.1992.10.2.249","volume":"10","author":"HS Friedman","year":"1992","unstructured":"Friedman HS, Krischer JP, Burger P et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study J Clin Oncol 1992 10: 249\u2013256","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR30","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/1097-0142(19940215)73:4<1297::AID-CNCR2820730427>3.0.CO;2-#","volume":"73","author":"LJ Ettinger","year":"1994","unstructured":"Ettinger LJ, Gaynon PS, Krailo MD et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children's Cancer Group Cancer 1994 73: 1297\u20131301","journal-title":"Cancer"},{"key":"BF1703213_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0305-7372(95)90023-3","volume":"21","author":"E van de Wall","year":"1995","unstructured":"van de Wall E, Beijnen JH, Rodenhuis S . High-dose chemotherapy regimens for solid tumors Cancer Treat Rev 1995 21: 105\u2013132","journal-title":"Cancer Treat Rev"},{"key":"BF1703213_CR32","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1160::AID-CNCR21>3.0.CO;2-F","volume":"85","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Kerby T, Fields S et al. Topotecan treatment of adults with primary malignant glioma Cancer 1999 85: 1160\u20131165","journal-title":"Cancer"},{"key":"BF1703213_CR33","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1200\/JCO.1994.12.12.2743","volume":"12","author":"AA Miller","year":"1994","unstructured":"Miller AA, Hargis JB, Lilenbaum RC et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a Cancer and Leukemia Group B study J Clin Oncol 1994 12: 2743\u20132750","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR34","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1200\/JCO.1996.14.12.3074","volume":"14","author":"EK Rowinsky","year":"1996","unstructured":"Rowinsky EK, Kaufman SH, Baker SD et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence J Clin Oncol 1996 14: 3074\u20133084","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.1997.15.1.148","volume":"15","author":"JR Murren","year":"1997","unstructured":"Murren JR, Anderson S, Fedele J et al. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer J Clin Oncol 1997 15: 148\u2013157","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.1998.16.3.945","volume":"16","author":"RL Saylors III","year":"1998","unstructured":"Saylors RL III, Stewart CF, Zamboni WC et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group study J Clin Oncol 1998 16: 945\u2013952","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR37","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/1096-911X(20001101)35:5<468::AID-MPO5>3.0.CO;2-P","volume":"35","author":"BH Kushner","year":"2000","unstructured":"Kushner BH, Kramer K, Meyers PA et al. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors Med Pediatr Oncol 2000 35: 468\u2013474","journal-title":"Med Pediatr Oncol"},{"key":"BF1703213_CR38","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1093\/jnci\/84.22.1703","volume":"22","author":"RJ Motzer","year":"1992","unstructured":"Motzer RJ, Bosl GJ . High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions J Natl Cancer Inst 1992 22: 1703\u20131709","journal-title":"J Natl Cancer Inst"},{"key":"BF1703213_CR39","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1200\/JCO.1998.16.5.1697","volume":"16","author":"F Boulad","year":"1998","unstructured":"Boulad F, Kernan NA, LaQuaglia MP et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma J Clin Oncol 1998 16: 1697\u20131706","journal-title":"J Clin Oncol"},{"key":"BF1703213_CR40","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/1097-0142(20010415)91:8<1510::AID-CNCR1159>3.0.CO;2-I","volume":"91","author":"K Kramer","year":"2001","unstructured":"Kramer K, Kushner BH, Heller G, Cheung NKV . Neuroblastoma metastatic to the central nervous system: the Memorial Sloan-Kettering Cancer Center experience and a literature review Cancer 2001 91: 1510\u20131519","journal-title":"Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703213","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:08:59Z","timestamp":1648058939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,1]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,9,1]]}},"alternative-id":["BF1703213"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703213","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9,1]]},"assertion":[{"value":"3 May 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2001","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2001","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}